Literature DB >> 19859732

Precursors of endometrial and ovarian carcinoma.

Robert J Kurman1, Thomas G McConnell.   

Abstract

This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary. While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma. For both, the morphologic and molecular genetic-defining characteristics of their respective precursor lesions are described in detail. Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19859732     DOI: 10.1007/s00428-009-0824-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  87 in total

Review 1.  Endometrial hyperplasia: is it time for a quantum leap to a new classification?

Authors:  R J Zaino
Journal:  Int J Gynecol Pathol       Date:  2000-10       Impact factor: 2.762

2.  Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.

Authors:  Kentaro Nakayama; Naomi Nakayama; Robert J Kurman; Leslie Cope; Gudrun Pohl; Yardena Samuels; Victor E Velculescu; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Biol Ther       Date:  2006-07-26       Impact factor: 4.742

3.  PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.

Authors:  R L Levine; C B Cargile; M S Blazes; B van Rees; R J Kurman; L H Ellenson
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

4.  Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases.

Authors:  K R Lee; J L Belinson
Journal:  Gynecol Oncol       Date:  1992-07       Impact factor: 5.482

5.  Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis.

Authors:  D S McMeekin; R A Burger; A Manetta; P DiSaia; M L Berman
Journal:  Gynecol Oncol       Date:  1995-10       Impact factor: 5.482

6.  Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.

Authors:  Lin Jia; Yongjuan Liu; Xiaofang Yi; Alexander Miron; Christopher P Crum; Beihua Kong; Wenxin Zheng
Journal:  Clin Cancer Res       Date:  2008-03-27       Impact factor: 12.531

7.  K-ras activation in premalignant and malignant epithelial lesions of the human uterus.

Authors:  T Enomoto; M Inoue; A O Perantoni; G S Buzard; H Miki; O Tanizawa; J M Rice
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

8.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.

Authors:  M Saegusa; M Hashimura; T Yoshida; I Okayasu
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

10.  Mutations of the beta-catenin gene in endometrial carcinomas.

Authors:  K Kobayashi; S Sagae; Y Nishioka; T Tokino; R Kudo
Journal:  Jpn J Cancer Res       Date:  1999-01
View more
  9 in total

1.  Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.

Authors:  Marta Bellone; Emiliano Cocco; Joyce Varughese; Stefania Bellone; Paola Todeschini; Karim El-Sahwi; Luisa Carrara; Federica Guzzo; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Deborah J Marshall; Alessandro D Santin
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

2.  Clinical significance of microRNA expressions in diagnosing uterine cancer and predicting lymph node metastasis.

Authors:  Changlong Hou; Guosheng Tan; Shiting Feng
Journal:  Tumour Biol       Date:  2014-07-31

3.  Does Preoperative Diagnosis of Endometrial Hyperplasia Necessitate Intraoperative Frozen Section Consultation?

Authors:  Gokhan Boyraz; Derman Başaran; Mehmet C Salman; Nejat Özgül; Kunter Yüce
Journal:  Balkan Med J       Date:  2016-11-01       Impact factor: 2.021

4.  Papillary mucinous metaplasia: a distinct precursor of mucinous adenocarcinoma of the endometrium.

Authors:  Su Hyun Yoo
Journal:  Int J Clin Exp Pathol       Date:  2022-02-15

5.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

6.  The duplicitous origin of ovarian cancer.

Authors:  Gil Mor; Ayesha Alvero
Journal:  Rambam Maimonides Med J       Date:  2013-01-30

7.  The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Authors:  Sandra Sernbo; Elin Gustavsson; Donal J Brennan; William M Gallagher; Elton Rexhepaj; Frida Rydnert; Karin Jirström; Carl Ak Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

8.  Combining endometrium sampling device and SurePath preparation to screen for endometrial carcinoma: a validation study.

Authors:  Jia Wen; Rui Chen; Jian Zhao; Yin Dong; Xi Yang; Qin-Ping Liao
Journal:  Chin Med J (Engl)       Date:  2015-03-05       Impact factor: 2.628

9.  Frozen Blastocyst Embryo Transfer: Comparison of Protocols and Factors Influencing Outcome.

Authors:  Aikaterini Eleftheriadou; Abraham Francis; Mark Wilcox; Kanna Jayaprakasan
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.